Cocrystal Pharma Stock Price, News & Analysis (NASDAQ:COCP) $1.85 +0.01 (+0.54%) (As of 11/29/2023 ET) Add Compare Share Share Today's Range$1.70▼$1.9050-Day Range$1.46▼$2.1352-Week Range$1.38▼$3.29Volume14,460 shsAverage Volume46,062 shsMarket Capitalization$18.81 millionP/E RatioN/ADividend YieldN/APrice Target$12.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Cocrystal Pharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside548.6% Upside$12.00 Price TargetShort InterestHealthy0.14% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.76Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.00) to ($1.87) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.19 out of 5 starsMedical Sector406th out of 949 stocksPharmaceutical Preparations Industry180th out of 435 stocks 3.5 Analyst's Opinion Consensus RatingCocrystal Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $12.00, Cocrystal Pharma has a forecasted upside of 548.6% from its current price of $1.85.Amount of Analyst CoverageCocrystal Pharma has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.14% of the float of Cocrystal Pharma has been sold short.Short Interest Ratio / Days to CoverCocrystal Pharma has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cocrystal Pharma has recently increased by 84.91%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCocrystal Pharma does not currently pay a dividend.Dividend GrowthCocrystal Pharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for COCP. Previous Next 2.1 News and Social Media Coverage News SentimentCocrystal Pharma has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Cocrystal Pharma this week, compared to 0 articles on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cocrystal Pharma insiders have not sold or bought any company stock.Percentage Held by Insiders25.06% of the stock of Cocrystal Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 13.43% of the stock of Cocrystal Pharma is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Cocrystal Pharma are expected to grow in the coming year, from ($2.00) to ($1.87) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cocrystal Pharma is -0.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cocrystal Pharma is -0.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCocrystal Pharma has a P/B Ratio of 0.61. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Cocrystal Pharma Stock (NASDAQ:COCP)Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.Read More COCP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart COCP Stock News HeadlinesNovember 29, 2023 | finance.yahoo.comCocrystal Pharma Highlights its Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West CoastNovember 27, 2023 | finance.yahoo.comCocrystal Pharma to Present at the NobleCon 19 Conference on December 4, 2023November 29, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 14, 2023 | benzinga.comCocrystal Pharma Stock (NASDAQ:COCP) Earnings Dates and Earning CallsNovember 14, 2023 | msn.comCOCP: Cocrystal Pharma reports 3rd quarter financial results and provides updates on clinical trials.November 13, 2023 | benzinga.comRecap: Cocrystal Pharma Q3 EarningsNovember 13, 2023 | finance.yahoo.comCocrystal Pharma Reports Third Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development ProgramsNovember 9, 2023 | finance.yahoo.comCocrystal Pharma to Discuss Progress with Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West CoastNovember 29, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 3, 2023 | markets.businessinsider.comBuy Rating Issued for Cocrystal Pharma Amid Advancements in Influenza and Coronavirus TreatmentsOctober 31, 2023 | finance.yahoo.comCocrystal Pharma Receives UK MHRA Authorization to Initiate Its Phase 2a Influenza Human Challenge Trial with Oral PB2 Inhibitor CC-42344October 5, 2023 | msn.comHC Wainwright & Co. Reiterates Cocrystal Pharma (COCP) Buy RecommendationOctober 2, 2023 | finance.yahoo.comCOCP: Cocrystal Pharma doses 1st subjects in the important CDI-988 clinical trial.August 16, 2023 | finance.yahoo.comCOCP: Cocrystal Pharma reports 2nd quarter 2023 financial results and provides updates on drug pipeline.August 15, 2023 | markets.businessinsider.comAnalyst Ratings for Cocrystal PharmaAugust 15, 2023 | markets.businessinsider.comCocrystal Pharma (COCP) Receives a Buy from H.C. WainwrightAugust 15, 2023 | markets.businessinsider.comNoble Financial Keeps Their Buy Rating on Cocrystal Pharma (COCP)August 14, 2023 | finance.yahoo.comCocrystal Pharma Reports Second Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development ProgramsAugust 11, 2023 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Immunocore Holdings (IMCR), Tyra Bioscience (TYRA)August 8, 2023 | finance.yahoo.comCocrystal Pharma Selects Novel Oral Protease Inhibitor CDI-988 as Norovirus LeadMay 31, 2023 | finance.yahoo.comCocrystal Pharma Receives HREC Approval to Initiate Phase 1 Study to Evaluate Oral Broad-Spectrum Coronavirus 3CL Protease Inhibitor CDI-988May 24, 2023 | msn.comHC Wainwright & Co. Maintains Cocrystal Pharma (COCP) Buy RecommendationMay 24, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on Cocrystal Pharma (COCP)May 17, 2023 | finance.yahoo.comCOCP: Cocrystal Pharma reports 1st quarter 2023 financial results and provides updates on drug pipeline.May 15, 2023 | finance.yahoo.comCocrystal Pharma Reports First Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development ProgramsMay 4, 2023 | finance.yahoo.comCocrystal Pharma Presents New Data from its CC-42344 Phase 1 Influenza A Study at the 7th Annual ISIRV Antiviral Group ConferenceApril 24, 2023 | finance.yahoo.comCocrystal Pharma Appoints Pharma Industry Veteran Fred Hassan to its Board of DirectorsSee More Headlines Receive COCP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cocrystal Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/15/2021Today11/29/2023Fiscal Year End12/31/2023Next Earnings (Estimated)4/03/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:COCP CUSIPN/A CIK1412486 Webwww.cocrystalpharma.com Phone(305) 425-1780FaxN/AEmployees12Year FoundedN/APrice Target and Rating Average Stock Price Target$12.00 High Stock Price Target$12.00 Low Stock Price Target$12.00 Potential Upside/Downside+566.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($2.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-38,840,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-54.10% Return on Assets-51.18% Debt Debt-to-Equity RatioN/A Current Ratio16.74 Quick Ratio16.74 Sales & Book Value Annual Sales$2.01 million Price / Sales9.11 Cash Flow$0.17 per share Price / Cash Flow10.40 Book Value$3.02 per share Price / Book0.60Miscellaneous Outstanding Shares10,170,000Free Float7,624,000Market Cap$18.31 million OptionableNot Optionable Beta1.24 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. Roger D. Kornberg Ph.D. (Age 76)Co-Founder, Chairman of the Board, Chief Scientist & Chairman of Scientific Advisory Board Comp: $125kDr. Sam Lee Ph.D. (Age 63)Co-Founder, Co-CEO & President Comp: $521.38kMr. James J. Martin CPA (Age 56)M.B.A., Co-CEO, CFO & Corporate Secretary Comp: $521.38kKey CompetitorsDURECTNASDAQ:DRRXUnicycive TherapeuticsNASDAQ:UNCYCorbus PharmaceuticalsNASDAQ:CRBPSynlogicNASDAQ:SYBXViracta TherapeuticsNASDAQ:VIRXView All CompetitorsInsidersPhillip Md Et Al FrostBought 1,015,229 shares on 4/4/2023Total: $2.00 M ($1.97/share)View All Insider Transactions COCP Stock Analysis - Frequently Asked Questions Should I buy or sell Cocrystal Pharma stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cocrystal Pharma in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" COCP shares. View COCP analyst ratings or view top-rated stocks. What is Cocrystal Pharma's stock price target for 2024? 1 Wall Street research analysts have issued 12 month target prices for Cocrystal Pharma's shares. Their COCP share price targets range from $12.00 to $12.00. On average, they anticipate the company's share price to reach $12.00 in the next year. This suggests a possible upside of 548.6% from the stock's current price. View analysts price targets for COCP or view top-rated stocks among Wall Street analysts. How have COCP shares performed in 2023? Cocrystal Pharma's stock was trading at $1.95 at the beginning of the year. Since then, COCP stock has decreased by 5.1% and is now trading at $1.85. View the best growth stocks for 2023 here. Are investors shorting Cocrystal Pharma? Cocrystal Pharma saw a increase in short interest in November. As of November 15th, there was short interest totaling 9,800 shares, an increase of 84.9% from the October 31st total of 5,300 shares. Based on an average daily volume of 27,100 shares, the days-to-cover ratio is presently 0.4 days. Currently, 0.1% of the shares of the company are short sold. View Cocrystal Pharma's Short Interest. When is Cocrystal Pharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 3rd 2024. View our COCP earnings forecast. How were Cocrystal Pharma's earnings last quarter? Cocrystal Pharma, Inc. (NASDAQ:COCP) issued its quarterly earnings data on Monday, November, 15th. The company reported ($0.48) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.48). When did Cocrystal Pharma's stock split? Shares of Cocrystal Pharma reverse split on Tuesday, October 11th 2022. The 1-12 reverse split was announced on Tuesday, October 11th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, October 11th 2022. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. What other stocks do shareholders of Cocrystal Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cocrystal Pharma investors own include Moderna (MRNA), Hello Group (MOMO), Intra-Cellular Therapies (ITCI), Impala Platinum (IMPUY), GenMark Diagnostics (GNMK), Gevo (GEVO), Auxly Cannabis Group (CBWTF), Bionano Genomics (BNGO), Blink Charging (BLNK) and Bilibili (BILI). How do I buy shares of Cocrystal Pharma? Shares of COCP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:COCP) was last updated on 11/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cocrystal Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.